Hyperglutamatergic cortico-striato-thalamo-cortical circuit breaker drugs alleviate tics in a transgenic circuit model of Tourette's syndrome

Brain Research

Volumn 1629, Issue , 2015, Pages 38-53

  Nordstrom, Eric J ^a,b   Bittner, Katie C ^a,c   McGrath, Michael J ^a   Parks, Clinton R ^a,d   Burton, Frank H ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^d Space NewsInc ^*  (United States)

Author keywords

Cortex; Dopamine; Glutamate; Somatosensory; Striatum; Tourette

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; GLUTAMIC ACID; SEROTONIN 2 ANTAGONIST;

ANIMAL; BAGG ALBINO MOUSE; CORPUS STRIATUM; DISEASE MODEL; DRUG EFFECTS; FEMALE; METABOLISM; MOUSE; NERVE CELL NETWORK; SOMATOSENSORY CORTEX; THALAMUS NUCLEUS; TICS; TOURETTE SYNDROME; TRANSGENIC MOUSE;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE AGONISTS; FEMALE; GLUTAMIC ACID; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; NERVE NET; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS; SOMATOSENSORY CORTEX; THALAMIC NUCLEI; TICS; TOURETTE SYNDROME;

EID: 84955471945     PISSN: 00068993     EISSN: 18726240     Source Type: Journal    
DOI: 10.1016/j.brainres.2015.09.032     Document Type: Article

References (107)

1. G.K. Aghajanian, and G.J. Marek Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release Brain Res. 825 1999 161 171
2. S.E. Ahmari, V.B. Risbrough, M.A. Geyer, and H.B. Simpson Impaired sensorimotor gating in unmedicated adults with obsessive-compulsive disorder Neuropsychopharmacology 37 5 2012 1216 1223
3. S.E. Ahmari, T. Spellman, N.L. Douglass, M.A. Kheirbek, H.B. Simpson, K. Deisseroth, J.A. Gordon, and R. Hen Repeated cortico-striatal stimulation generates persistent OCD-like behavior Science 340 2013 1234 1239
4. S.E. Ahmari, and D.D. Dougherty Dissecting OCD circuits: from animal models to targeted treatments Depress Anxiety 32 8 2015 550 562
5. R.L. Albin, and J.W. Mink Recent advances in Tourette syndrome research Trends Neurosci. 29 3 2006 175 182
6. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 5th ed. 2013 APA Washington, DC
7. K. Bakuridze, E. Savli, N. Gongadze, D.B. Baş, and A. Gepdiremen Protection in glutamate-induced neurotoxicity by imidazoline receptor agonist moxonidine Int. J. Neurosci. 119 10 2009 1705 1717
8. J.A. Barone, R.H. Bierman, J.W. Cornish, A. Hsuan, N.D. Drake, and J.L. Colaizzi Safety evaluation of ritanserin - an investigational serotonin antagonist Drug Intell. Clin. Pharm. 20 10 1986 770 775
9. S. Bohlhalter, A. Goldfine, S. Matteson, G. Garraux, T. Hanakawa, K. Kansaku, R. Wurzman, and M. Hallett Neural correlates of tic generation in Tourette syndrome: an event-related functional MRI study Brain 129 2006 2029 2037
10. C. Bonnier, M.C. Nassogne, and P. Evrard Ketanserin treatment of Tourette's syndrome in children Am. J. Psychiatry 156 1999 1122 1123
11. M. Bortolato, K. Chen, S.C. Godar, G. Chen, W. Wu, I. Rebrin, M.R. Farrell, A.L. Scott, C.L. Wellman, and J.C. Shih Social deficits and perseverative behaviors, but not overt aggression, in MAO-A hypomorphic mice Neuropsychopharmacology 36 13 2011 2674 2688
12. H.C. Breiter, S.L. Rauch, K.K. Kwong, J.R. Baker, R.M. Weisskoff, D.N. Kennedy, A.D. Kendrick, T.L. Davis, A. Jiang, M.S. Cohen, C.E. Stern, J.W. Belliveau, L. Baer, R.L. O'Sullivan, C.R. Savage, M.A. Jenike, and B.R. Rosen Functional magnetic resonance imaging of symptom provocation in obsessive-compulsive disorder Arch. Gen. Psychiatry 53 7 1996 595 606
13. R.N. Brogden, and E.M. Sorkin Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease Drugs 40 6 1990 903 949
14. R.D. Bruun, and C.L. Budman Risperidone as a treatment for Tourette's syndrome J. Clin. Psychiatry 57 1 1996 29 31
15. E. Burguiere, P. Monteiro, G. Feng, and A.M. Graybiel Optogenetic stimulation of lateral orbitofronto-striatal pathway suppresses compulsive behaviors Science 340 2013 1243 1246
16. K. Burke, and P.J. Lombroso Animal models of Tourette syndrome M. LeDoux, Animal Models of Movement Disorders 2004 Elsevier Academic Press Burlington, MA 441 448
17. F.H. Burton, K.W. Hasel, F.E. Bloom, and J.G. Sutcliffe Pituitary hyperplasia and gigantism in mice caused by a cholera toxin transgene Nature 350 1991 74 77
18. K.M. Campbell, R.M. Rohland, M.J. McGrath, S.D. Satoskar, and F.H. Burton Detecting subtle differences in behavior using waveform display analysis Physiol. Behav. 64 1998 83 91
19. K.M. Campbell, L. de Lecea, D.M. Severynse, M.G. Caron, M.J. McGrath, S.B. Sparber, L.Y. Sun, and F.H. Burton OCD-Like behaviors caused by a neuropotentiating transgene targeted to cortical and limbic D1+ neurons J. Neurosci. 19 12 1999 5044 5053
20. K.M. Campbell, M.J. McGrath, and F.H. Burton Differential response of cortical-limbic neuropotentiated compulsive mice to D1 and D2 antagonists Eur. J. Pharmacol. 371 1999 103 111
21. K.M. Campbell, M.J. McGrath, and F.H. Burton Behavioral effects of cocaine on a transgenic mouse model of cortical-limbic compulsion Brain Res. 833 1999 216 224
22. K.M. Campbell, M.B. Veldman, M.J. McGrath, and F.H. Burton TS+OCD-like neuropotentiated mice are supersensitive to seizure induction NeuroReport 11 2000 2335 2338
23. M.L. Carlsson On the role of cortical glutamate in obsessive-compulsive disorder and attention-deficit hyperactivity disorder, two phenomenologically antithetical conditions Acta Psychiatr. Scand. 102 2000 401 413
24. L. Castellan Baldan, K.A. Williams, J.D. Gallezot, V. Pogorelov, M. Rapanelli, M. Crowley, G.M. Anderson, E. Loring, R. Gorczyca, E. Billingslea, S. Wasylink, K.E. Panza, A.G. Ercan-Sencicek, K. Krusong, B.L. Leventhal, H. Ohtsu, M.H. Bloch, Z.A. Hughes, J.H. Krystal, L. Mayes, I. de Araujo, Y.S. Ding, M.W. State, and C. Pittenger Histidine decarboxylase deficiency causes Tourette syndrome: parallel findings in humans and mice Neuron 81 2014 77 90
25. C.A. Castro, J.B. Hogan, K.A. Benson, C.W. Shehata, and M.R. Landauer Behavioral effects of vehicles: DMSO, ethanol, Tween-20, Tween-80, and emulphor-620 Pharmacol. Biochem. Behav. 50 4 1995 521 526
26. A. Ceccherini-Nelli, and M. Guazzelli Treatment of refractory OCD with the dopamine agonist bromocriptine J. Clin. Psychiatry 55 1994 415 416
27. D.L. Ceulemans, M.L. Hoppenbrouwers, Y.G. Gelders, and A.J. Reyntjens The influence of ritanserin, a serotonin antagonist, in anxiety disorders: a double-blind placebo-controlled study versus lorazepam Pharmacopsychiatry 18 1985 303 305
28. K. Chakrabarty, S. Bhattacharyya, R. Christopher, and S. Khanna Glutamatergic Dysfunction in OCD Neuropsychopharmacol 30 2005 1735 1740
29. J.T. Cheng, and D.Y. Kuo Both alpha1-adrenergic and D(1)-dopaminergic neurotransmissions are involved in phenylpropanolamine-mediated feeding suppression in mice Neurosci. Lett. 347 2 2003 136 138
30. J.A. Church, and B.L. Schlaggar Pediatric Tourette syndrome: insights from recent neuroimaging studies J. Obsessive Compuls. Relat. Disord. 3 2014 386 393
31. R. Ciccocioppo, S. Angeletti, G. Colombo, G. Gessa, and M. Massi Autoradiographic analysis of 5-HT2A binding sites in the brain of Sardinian alcohol-preferring and nonpreferring rats Eur. J. Pharmacol. 373 1 1999 13 19
32. D.J. Cohen, M.A. Riddle, and J.F. Leckman Pharmacotherapy of Tourette's syndrome and associated disorders Psychiatr. Clin. North Am. 15 1992 109 129
33. P. Danjou, D. Warot, T. Hergueta, L. Lacomblez, P. Bouhours, and A.J. Puech Comparative study of the psychomotor and antistress effects of ritanserin, alprazolam and diazepam in healthy subjects: some trait anxiety-independent responses Int. Clin. Psychopharmacol. 7 2 1992 73 79
34. D. Denys, F. de Vries, D. Cath, M. Figee, N. Vulink, D.J. Veltman, T.F. van der Doef, R. Boellaard, H. Westenberg, A. van Balkom, A.A. Lammertsma, and B.N. van Berckel Dopaminergic activity in Tourette syndrome and obsessive-compulsive disorder Eur. Neuropsychopharmacol. 23 11 2013 1423 1431
35. M.P. Dixit, P.P. Thakre, A.S. Pannase, M.M. Aglawe, B.G. Taksande, and N.R. Kotagale Imidazoline binding sites mediates anticompulsive-like effect of agmatine in marble-burying behavior in mice Eur. J. Pharmacol. 732 2014 26 31
36. S.A. Edgley, and R.N. Lemon Experiments using transcranial magnetic brain stimulation in man could reveal important new mechanisms in motor control J. Physiol. 521 1999 565
37. A.G. Ercan-Sencicek, A.A. Stillman, A.K. Ghosh, K. Bilguvar, B.J. O'Roak, C.E. Mason, T. Abbott, A. Gupta, R.A. King, D.L. Pauls, J.A. Tischfield, G.A. Heiman, H.S. Singer, D.L. Gilbert, P.J. Hoekstra, T.M. Morgan, E. Loring, K. Yasuno, T. Fernandez, S. Sanders, A. Louvi, J.H. Cho, S. Mane, C.M. Colangelo, T. Biederer, R.P. Lifton, M. Gunel, and M.W. State L-histidine decarboxylase and Tourette's syndrome N Engl. J. Med. 362 2010 1901 1908
38. C.A. Fairbanks, and G.L. Wilcox Moxonidine, a selective alpha2-adrenergic and imidazoline receptor agonist, produces spinal antinociception in mice J. Pharmacol. Exp. Ther. 290 1999 403 412
39. M.A. Fox, M.G. Panessiti, F.S. Hall, G.R. Uhl, and D.L. Murphy An evaluation of the serotonin system and perseverative, compulsive, stereotypical, and hyperactive behaviors in dopamine transporter (DAT) knockout mice Psychopharmacology 227 2013 685 695
40. M. Frankel, J.L. Cummings, M.M. Robertson, M.R. Trimble, M.A. Hill, and D.F. Benson Obsessions and compulsions in Gilles de la Tourette's syndrome Neurology 36 1986 378 382
41. B. Gao, and M.G. Cutler Effects of acute and subchronic administration of ritanserin on the social behaviour of mice Neuropharmacology 32 3 1993 265 272
42. E.L. Gibson, A.M. Barnfield, and G. Curzon Evidence that mCPP-induced anxiety in the plus-maze is mediated by postsynaptic 5-HT2C receptors but not by sympathomimetic effects Neuropharmacology 33 3-4 1994 457 465
43. D.L. Gilbert, G. Sethuraman, L. Sine, S. Peters, and F.R. Sallee Tourette's syndrome improvement with pergolide in a randomized, double-blind, crossover trial Neurology 54 2000 1310 1315
44. D.L. Gilbert, A.S. Bansal, G. Sethuraman, F.R. Sallee, J. Zhang, T. Lipps, and E.M. Wassermann Association of cortical disinhibition with tic, ADHD and OCD severity in Tourette Syndrome Mov. Disord. 19 2004 416 425
45. D.L. Gilbert, C.L. Budman, H.S. Singer, R. Kurlan, and R.E. Chipkin A D1 receptor antagonist, ecopipam, for treatment of tics in Tourette syndrome Clin. Neuropharmacol. 37 1 2014 26 30
46. S.C. Godar, L.J. Mosher, H.J. Strathman, A.M. Gochi, C.M. Jones, S.C. Fowler, and M. Bortolato The D1CT-7 mouse model of Tourette syndrome displays sensorimotor gating deficits in response to spatial confinement Br. J. Pharmacol. 2015 10.1111/bph.13243 (Epub ahead of print)
47. C.G. Goetz Clonidine and clonazepam in Tourette syndrome Adv. Neurol. 58 1992 245 251
48. J.E. Grant, B.L. Odlaug, and S.W. Kim N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study Arch. Gen. Psychiatry 66 7 2009 756 763
49. J.E. Grant, B.L. Odlaug, D.W. Black, T. Fong, M. Davtian, R. Chipkin, and S.W. Kim A single-blind study of'as-needed' ecopipam for gambling disorder Ann. Clin. Psychiatry 26 3 2014 179 186
50. P. Grant, L. Lougee, M. Hirschtritt, and S.E. Swedo An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder J. Child. Adolesc. Psychopharmacol. 17 6 2007 761 767
51. H. Homayoun, and B. Moghaddam NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons J. Neurosci. 27 43 2007 11496 11500
52. J. Hosie, D.J. Stott, J.I. Robertson, and S.G. Ball Does acute serotonergic type-2 antagonism reduce blood pressure? Comparative effects of single doses of ritanserin and ketanserin in essential hypertension J. Cardiovasc. Pharmacol. 10 Suppl 3 1987 S86 S88
53. D.M. Jackson, O.F. Jenkins, and S.B. Ross The motor effects of bromocriptine - a review Psychopharmacology 95 1988 433 446
54. R.L. Jakab, and P.S. Goldman-Rakic 5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites Proc. Natl. Acad. Sci. USA 95 2 1998 735 740
55. D. Joel Current animal models of obsessive compulsive disorder: A critical review Prog. Neuropsychopharmacol. Biol. Psychiatry 30 3 2006 374 388
56. P.S. Kalanithi, W. Zheng, Y. Kataoka, M. DiFiglia, H. Grantz, C.B. Saper, M.L. Schwartz, J.F. Leckman, and F.M. Vaccarino Altered parvalbumin-positive neuron distribution in basal ganglia of individuals with Tourette syndrome Proc. Natl. Acad. Sci. USA 102 2005 13307 13312
57. I. Karagiannidis, S. Dehning, P. Sandor, Z. Tarnok, R. Rizzo, T. Wolanczyk, M. Madruga-Garrido, J. Hebebrand, M.M. Nöthen, G. Lehmkuhl, L. Farkas, P. Nagy, U. Szymanska, Z. Anastasiou, V. Stathias, C. Androutsos, V. Tsironi, A. Koumoula, C. Barta, P. Zill, P. Mir, N. Müller, C. Barr, and P. Paschou Support of the histaminergic hypothesis in Tourette syndrome: association of the histamine decarboxylase gene in a large sample of families J. Med. Genet. 50 2013 760 764
58. Y. Kataoka, P.S. Kalanithi, H. Grantz, M.L. Schwartz, C. Saper, J.F. Leckman, and F.M. Vaccarino Decreased number of parvalbumin and cholinergic interneurons in the striatum of individuals with Tourette syndrome J. Comp. Neurol. 518 2010 277 291
59. D.L. Lafleur, C. Pittenger, B. Kelmendi, T. Gardner, S. Wasylink, R.T. Malison, G. Sanacora, J.H. Krystal, and V. Coric N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder Psychopharmacology 184 2 2006 254 256
60. D.G. Lichter, and L.A. Jackson Predictors of clonidine response in Tourette syndrome: implications and inferences J. Child. Neurol. 11 1996 93 97
61. A. Mantovani, S.H. Lisanby, F. Pieraccini, M. Ulivelli, P. Castrogiovanni, and S. Rossi Repetitive transcranial magnetic stimulation (rTMS) in the treatment of obsessive-compulsive disorder (OCD) and Tourette's syndrome (TS) Int. J. Neuropsychopharmacol. 9 1 2006 95 100
62. G.J. Marek, and G.K. Aghajanian The electrophysiology of prefrontal serotonin systems: therapeutic implications for mood and psychosis Biol. Psychiatry 44 11 1998 1118 1127
63. G.J. Marek, and G.K. Aghajanian 5-HT2A receptor or alpha1-adrenoceptor activation induces excitatory postsynaptic currents in layer V pyramidal cells of the medial prefrontal cortex Eur. J. Pharmacol. 367 2-3 1999 197 206
64. M.J. McGrath, K.M. Campbell, M.B. Veldman, and F.H. Burton Anxiety in a transgenic mouse model of cortical-limbic neuropotentiated compulsive behavior Behav. Pharmacol. 10 1999 435 443
65. M.J. McGrath, K.M. Campbell, and F.H. Burton The role of cognitive and affective processing in a transgenic mouse model of cortical-limbic neuropotentiated compulsive behavior Behav. Neurosci. 113 1999 1249 1256
66. M.J. McGrath, K.M. Campbell, C.R. Parks III, and F.H. Burton Glutamatergic drugs exacerbate symptomatic behavior in a transgenic model of comorbid Tourette's Syndrome and obsessive-compulsive disorder Brain Res. 877 2000 23 30
67. L. Menzies, S.R. Chamberlain, A.R. Laird, S.M. Thelen, B.J. Sahakian, and E.T. Bullmore Integrating evidence from neuroimaging and neuropsychological studies of obsessive-compulsive disorder: the orbitofronto-striatal model revisited Neurosci. Biobehav. Rev. 32 3 2008 525 549
68. M.R. Milad, and S.L. Rauch Obsessive-compulsive disorder: beyond segregated cortico-striatal pathways Trends Cogn. Sci. 16 1 2012 43 51
69. J.W. Mink Basal ganglia dysfunction in Tourette's syndrome: a new hypothesis Pediatr. Neurol. 25 3 2001 190 198 2001
70. K. Minzer, O. Lee, J.J. Hong, and H.S. Singer Increased prefrontal D2 protein in Tourette syndrome: a postmortem analysis of frontal cortex and striatum J. Neurol. Sci. 219 2004 55 61
71. E.J. Nestler Schizophrenia. An emerging pathophysiology [news; comment] Nature 385 6617 1997 578 579
72. I. Ninan, and S.K. Kulkarni 5-HT2A receptor antagonists block MK-801-induced stereotypy and hyperlocomotion Eur. J. Pharmacol. 358 2 1998 111 116
73. E.J. Nordstrom, and F.H. Burton A transgenic model of comorbid Tourette's syndrome and obsessive-compulsive disorder circuitry Mol. Psychiatry 7 2002 617 625
74. O. Penagarikano, B.S. Abrahams, E.I. Herman, K.D. Winden, A. Gdalyahu, H. Dong, L.I. Sonnenblick, R. Gruver, J. Almajano, A. Bragin, P. Golshani, J.T. Trachtenberg, E. Peles, and D.H. Geschwind Absence of CNTNAP2 leads to epilepsy, neuronal migration abnormalities, and core autism-related deficits Cell 147 2011 235 246
75. B. Peterson, M.A. Riddle, D.J. Cohen, L.D. Katz, J.C. Smith, M.T. Hardin, and J.F. Leckman Reduced basal ganglia volumes in Tourette's syndrome using three-dimensional reconstruction techniques from magnetic resonance images Neurology 43 1993 941 949
76. B.S. Peterson, P. Skudlarski, A.W. Anderson, H. Zhang, J.C. Gatenby, C.M. Lacadie, J.F. Leckman, and J.C. Gore A functional magnetic resonance imaging study of tic suppression in Tourette syndrome Arch. Gen. Psychiatry 55 1998 326 333
77. C. Pittenger, M.H. Bloch, and K. Williams Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment Pharmacol. Ther. 132 3 2011 314 332
78. V. Pogorelov, M. Xu, H.R. Smith, G.F. Buchanan, and C. Pittenger Corticostriatal interactions in the generation of tic-like behaviors after local striatal disinhibition Exp. Neurol. 265 2015 122 128
79. M. Rapanelli, L.R. Frick, V. Pogorelov, K.T. Ota, E. Abbasi, H. Ohtsu, and C. Pittenger Dysregulated intracellular signaling in the striatum in a pathophysiologically grounded model of Tourette syndrome Eur. Neuropsychopharmacol. 24 2014 1896 1906
80. M.M. Robertson Tourette syndrome, associated conditions and the complexities of treatment Brain 123 2000 425 462
81. D.R. Rosenberg, F.P. MacMaster, M.S. Keshavan, K.D. Fitzgerald, C.M. Stewart, and G.J. Moore Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine J. Am. Acad. Child. Adolesc. Psychiatry 39 9 2000 1096 1103
82. R. Sah, and F.R. Sallee Dopaminergic neurotransmission in Tourette's syndrome: a current update A. Sidhu, M. Laruelle, P. Vernier, Dopamine Receptors and Transporters: Function, Imaging, and Clinical Implication 2nd ed. 2002 Marcel Dekker Inc. New York, NY 369 389
83. F.R. Sallee, R. Kurlan, C.G. Goetz, H. Singer, L. Scahill, G. Law, V.M. Dittman, and P.B. Chappell Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study J. Am. Acad. Child. Adolesc. Psychiatry 39 3 2000 292 299
84. P.W. Sheldon, and G.K. Aghajanian Excitatory responses to serotonin (5-HT) in neurons of the rat piriform cortex: evidence for mediation by 5-HT1C receptors in pyramidal cells and 5-HT2 receptors in interneurons Synapse 9 1991 208 218
85. Y. Shirasaki, M. Sugimura, and T. Sato Bromocriptine, an ergot alkaloid, inhibits excitatory amino acid release mediated by glutamate transporter reversal Eur. J. Pharmacol. 643 1 2010 48 57
86. T.L. Simpson, A.J. Saxon, C.W. Meredith, C.A. Malte, B. McBride, L.C. Ferguson, C.A. Gross, K.L. Hart, and M. Raskind A pilot trial of the alpha-1 adrenergic antagonist, prazosin, for alcohol dependence Alcohol. Clin. Exp. Res. 33 2 2009 255 263
87. H.S. Singer, C. Morris, and M. Grados Glutamatergic modulatory therapy for Tourette syndrome Med. Hypotheses 74 5 2010 862 867
88. S.E. Swedo, P. Pietrini, H.L. Leonard, M.B. Schapiro, D.C. Rettew, E.L. Goldberger, S.I. Rapoport, J.L. Rapoport, and C.L. Grady Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder. Revisualization during pharmacotherapy Arch. Gen. Psychiatry 49 1992 690 694
89. N.R. Swerdlow, and A.N. Sutherland Using animal models to develop therapeutics for Tourette Syndrome Pharmacol. Ther. 108 3 2005 281 293
90. N.C. Swerdlow, and A.N. Sutherland Preclinical models relevant to Tourette syndrome Adv. Neurol. 99 2006 69 88
91. B.G. Taksande, N.R. Kotagale, M.R. Patel, G.P. Shelkar, R.R. Ugale, and C.T. Chopde Agmatine, an endogenous imidazoline receptor ligand modulates ethanol anxiolysis and withdrawal anxiety in rats Eur. J. Pharmacol. 637 1-3 2010 89 101
92. M. Tanabe, Y. Kino, M. Honda, and H. Ono Presynaptic I1-imidazoline receptors reduce GABAergic synaptic transmission in striatal medium spiny neurons J. Neurosci. 26 6 2006 1795 1802
93. M. Tanabe, M. Hashimoto, and H. Ono Imidazoline I(1) receptor-mediated reduction of muscle rigidity in the reserpine-treated murine model of Parkinson's disease Eur. J. Pharmacol. 589 1-3 2008 102 105
94. J.T. Ting, and G. Feng Glutamatergic synaptic dysfunction and obsessive-compulsive disorder Curr. Chem. Genom. 2 2008 62 75
95. A.J. Verkerk, C.A. Mathews, M. Joosse, B.H. Eussen, P. Heutink, and B.A. Oostra Tourette Syndrome Association International Consortium for Genetics. CNTNAP2 is disrupted in a family with Gilles de la Tourette syndrome and obsessive compulsive disorder Genomics 82 2003 1 9
96. L. Wang, H.B. Simpson, and S.C. Dulawa Assessing the validity of current mouse genetic models of obsessive-compulsive disorder Behav. Pharmacol. 20 2 2009 119 133
97. Z. Wang, T.V. Maia, R. Marsh, T. Colibazzi, A. Gerber, and B.S. Peterson The neural circuits that generate tics in Tourette's syndrome Am. J. Psychiatry 168 2011 1326 1337
98. P.J. Wellman, and B.T. Davies Reversal of cirazoline- and phenylpropanolamine-induced anorexia by the alpha1-receptor antagonist prazosin Pharmacol. Biochem. Behav. 42 1 1992 97 100
99. P.J. Wellman, L.R. McMahon, T. Green, and A. Tole Effects of the alpha 1a-adrenoceptor antagonist RS-17053 on phenylpropanolamine-induced anorexia in rats Pharmacol. Biochem. Behav. 57 1-2 1997 281 284
100. D.L. Willins, and H.Y. Meltzer Direct injection of 5-HT2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats J. Pharmacol. Exp. Ther. 282 2 1997 699 706
101. S.S. Wolf, D.W. Jones, M.B. Knable, J.G. Gorey, K.S. Lee, T.M. Hyde, R. Coppola, and D.R. Weinberger Tourette syndrome: prediction of phenotypic variation in monozygotic twins by caudate nucleus D2 receptor binding Science 273 5279 1996 1225 1227
102. K. Wu, G.L. Hanna, D.R. Rosenberg, and P.D. Arnold The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder Pharmacol. Biochem. Behav. 100 4 2012 726 735
103. M. Xu, A. Kobets, J.C. Du, J. Lennington, L. Li, M. Banasr, R.S. Duman, F.M. Vaccarino, R.J. DiLeone, and C. Pittenger Targeted ablation of cholinergic interneurons in the dorsolateral striatum produces behavioral manifestations of Tourette syndrome Proc. Natl. Acad. Sci. USA 112 2015 893 898
104. M. Xu, L. Li, H. Ohtsu, and C. Pittenger Histidine decarboxylase knockout mice, a genetic model of Tourette syndrome, show repetitive grooming after induced fear Neurosci. Lett. 595 2015 50 53
105. M.A. Zeiger, M. Saji, Y. Gusev, W.H. Westra, Y. Takiyama, W.C. Dooley, L.D. Kohn, and M.A. Levine Thyroid-specific expression of cholera toxin A1 subunit causes thyroid hyperplasia and hyperthyroidism in transgenic mice Endocrinology 138 1997 3133 3140
106. Q.M. Zhu, J.D. Lesnick, J.R. Jasper, S.J. MacLennan, M.P. Dillon, R.M. Eglen, and D.R. Blue Jr Cardiovascular effects of rilmenidine, moxonidine and clonidine in conscious wild-type and D79N alpha2A adrenoceptor transgenic mice Br. J. Pharmacol. 126 6 1999 1522 1530
107. U. Ziemann, W. Paulus, and A. Rothenberger Decreased motor inhibition in Tourette's disorder: evidence from transcranial magnetic stimulation Am. J. Psychiatry 154 1997 1277 1284